de la Morena Valenzuela G, Ruipérez Abizanda J A, Picó Aracil F, García García J, Jaén Armand E, Salas Nieto J
Unidad de Cardiología-Hemodinámica, Hospital Virgen de la Arrixaca, Murcia.
Rev Esp Cardiol. 1990 May;43(5):310-5.
The effect of one intravenous dose of verapamil on left ventricular diastolic and systolic flow was studied by Doppler-echocardiography in 31 patients with hypertrophic cardiomyopathy. On diastolic flow, verapamil induced a decrease in "a" wave velocity (1.02 + 0.37 vs 0.91 + 0.29 m/seg, p less than 0.01), and in its relation with maximal protodiastolic velocity (1.08 + 0.56 vs 0.89 + 0.37, p less than 0.01), and a shortening in the isovolumic relaxation period (0.076 + 0.031 vs 0.068 + 0.02, p less than 0.05). On the ejection flow, verapamil decreased the peak velocity (2.82 + 1.28 vs 2.42 + 1.18 m/seg, p less than 0.001). Nor age, sex, ventricular mass, gradient, neither hypertrophic cardiomyopathy's classification relates with changes after intravenous verapamil. There were no adverse effects. This study by Doppler-echocardiography confirms the beneficial ++ effect of intravenous verapamil in patients with hypertrophic cardiomyopathy not only on gradient reduction but also in the improvement on left ventricular diastolic function.
通过多普勒超声心动图研究了31例肥厚型心肌病患者静脉注射一剂维拉帕米对左心室舒张和收缩血流的影响。在舒张血流方面，维拉帕米使“a”波速度降低（1.02±0.37对0.91±0.29m/秒，p<0.01），及其与舒张早期最大速度的关系降低（1.08±0.56对0.89±0.37，p<0.01），等容舒张期缩短（0.076±0.031对0.068±0.02，p<0.05）。在射血血流方面，维拉帕米降低了峰值速度（2.82±1.28对2.42±1.18m/秒，p<0.001）。年龄、性别、心室质量、压力阶差以及肥厚型心肌病的分类均与静脉注射维拉帕米后的变化无关。未出现不良反应。这项多普勒超声心动图研究证实了静脉注射维拉帕米对肥厚型心肌病患者不仅在降低压力阶差方面，而且在改善左心室舒张功能方面都有有益作用。
